Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation

International Journal of Cancer

Volumn 118, Issue 10, 2006, Pages 2448-2454

  Nakamura, Yukari ^a   Sato, Hiroyuki ^a   Motokura, Toru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clonal evolution; Drug resistance; Multistep tumorigenesis; Natural selection

Indexed keywords

COMPLEMENTARY DNA; CYCLOSPORIN A; CYTARABINE; CYTIDINE DEAMINASE; DOXORUBICIN; GLYCOPROTEIN P; METHOTREXATE; NUCLEOSIDE TRANSPORTER; PROTEIN P53; PROTEIN SLC29A1; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IN VIVO STUDY; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE MYC; PLOIDY; PRIORITY JOURNAL; REPRODUCIBILITY; RISK FACTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; FIBROBLASTS; GENE EXPRESSION REGULATION; GENES, MYC; NEOPLASMS; P-GLYCOPROTEIN; PLOIDIES; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; SELECTION (GENETICS); TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33646407094     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21691     Document Type: Article

References (40)

1. Foulds L. Tumor progression. Cancer Res 1957;17:355-6.
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-33.
5. Chikatsu N, Nakamura Y, Sato H, Fujita T, Asano S, Motokura T. p53 mutations and tetraploids under r- and K-selection. Oncogene 2002;21:3043-9.
6. MacArthur RH, Wilson EO. The theory of island biogeography. Princeton, New Jersey: Princeton University Press, 1967.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
8. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-20.
9. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
10. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
11. Han JW, Dionne CA, Kedersha NL, Goldmacher VS. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res 1997;57:176-82.
12. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, Motokura T. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)-bearing B-cell malignancies and/ or mantle cell lymphoma. Blood 1997;89:965-74.
13. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000;7:1063-6.
14. Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, Nolan GP. Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci USA 1995;92:9146-50.
15. Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B, Mehlen P. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997;57:2661-7.
16. Deuchars KL, Duthie M, Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992;1130:157-65.
17. Dimanche-Boitrel MT, Micheau O, Hammann A, Haugg M, Eymin B, Chauffert B, Solary E. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer 1998;77:796-802.
18. Alderisio M, Cenci M, Valli C, Russo A, Bazan V, Dardanoni G, Cucciarre S, Carreca I, Macaluso MP, Tomasino RM, Vecchione A. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder. Anticancer Res 1998;18:4225-30.
19. Takanishi DM, Jr., Hart J, Covarelli P, Chappell R, Michelassi F. Ploidy as a prognostic feature in colonic adenocarcinoma. Arch Surg 1996;131:587-92.
20. de Graaff WE, Sleijfer DT, de Jong B, Dam A, Schraffordt Koops H, Oosterhuis JW. Significance of aneuploid stemlines in testicular non-seminomatous germ cell tumors. Cancer 1993;72:1300-4.
21. Watanabe A, Inokuchi K, Yamaguchi H, Mizuki T, Tanosaki S, Shimada T, Dan K. Near-triploidy and near-tetraploidy in hematological malignancies and mutation of the p53 gene. Clin Lab Haematol 2004;26:25-30.
22. Wu GS, El-Diery WS. p53 and chemosensitivity. Nat Med 1996;2:255-6.
23. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
24. Delia D, Mizutani S, Lamorte G, Goi K, Iwata S, Pierotti MA. p53 activity and chemotherapy. Nat Med 1996;2:724-5.
25. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993;8:2457-67.
26. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
27. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
28. Kaaijk P, Kaspers GJ, Van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 2003;88:775-81.
29. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB. Quantitative analysis of MDRl (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-4.
30. Gregorcyk S, Kang Y, Brandt D, Kolm P, Singer G, Perry RR. p-Glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 1996;3:8-14.
31. Yeh KH, Chen CL, Shun CT, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL. Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. J Clin Gastroenterol 1998;26:274-8.
32. Materna V, Pleger J, Hoffmann U, Lage H. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004;94:152-60.
33. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999;94:1086-99.
34. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994;12:2453-9.
35. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002;2:221-5.
36. Johnstone RW, Ruefti AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000;38:1-11.
37. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
38. Sato H, Nakamura Y, Motokura T. Differential 14-3-30 DNA methylation and expression in c-myc- and activated H-ras-transfromed cells under r- and K-selection. Cancer Lett, in press.
39. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 1998;103:1096-103.
40. Wright AM, Paterson AR, Sowa B, Akabutu JJ, Grundy PE, Gati WP. Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. Br J Haematol 2002;116:528-37.